Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03339700

Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult Clinical Trial

Official title:
Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide (BUCY2) Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia

Clinical Trial Summary

The main purpose of the project is to evaluate the disease free survival and overall survival in patients diagnosed with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) adding gemcitabine to the standard institutional conditioning regimen based on two alkylating drugs, reduced busulfan and cyclophosphamide (reduced BUCY 2).

Clinical Trial Description

In the last decade, hematopoietic stem cell transplantation (HSCT) has become an efficient strategy for the treatment of high risk acute lymphoblastic leukemias. Lymphoid acute leukemias (ALL) are considered malignant clonal diseases of the hematopoietic stem cells, and represent a therapeutic challenge due to the high relapse rate and mortality using conventional chemotherapy regimens. Many studies have shown a decrease in relapse and an increase in overall survival with allogeneic HSCT, however, despite the fact that results in ALL have improved in the past years, achieving complete remission (CR) in approximately 75% of the patients, the relapse rate remains high and long term survival is lower than 50% depending on age and disease characteristics. On the other hand, it has been stated that relapse is higher when an allo-HSCT is performed in second CR, obtaining poorer results compared to performing HSCT in first CR, although better than chemotherapy alone (87% probability of relapse).

It is necessary to implement strategies that increase efficiency of pre transplant conditioning regimens in patients diagnosed with ALL undergoing an allo-HSCT in order to reduce relapse and increase overall survival. The hypothesis is that adding gemcitabine to the standard institutional conditioning regimen (reduced BUCY 2) in patients with ALL undergoing an allo-HSCT, the relapse free survival as well as the overall survival will improve, because it has been demonstrated in other malignant hematological diseases that gemcitabine plus two alkylating agents, facilitates synergism with busulfan and melphalan, inhibiting the DNA damage repair and causing a higher cytotoxic effect. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03339700
Study type Interventional
Source Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Contact Eucario Leon Rodriguez, M.D.
Phone 525554870900
Email eucarios@hotmail.com
Status Recruiting
Phase Phase 2
Start date September 15, 2018
Completion date September 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Not yet recruiting NCT05895201 - High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD Phase 1/Phase 2
Recruiting NCT06060782 - Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine Phase 1
Not yet recruiting NCT05809284 - Determining the Mechanisms of Loss of CAR T Cell Persistence
Terminated NCT03705507 - International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia Phase 1/Phase 2
Recruiting NCT04605666 - CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT06206174 - TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05127148 - RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL
Not yet recruiting NCT05909059 - CAR T-cell Therapy in Patients With Renal Dysfunction Phase 2
Recruiting NCT05750706 - Prospective Observational Study on Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative
Withdrawn NCT03982992 - Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab Phase 2
Not yet recruiting NCT04688983 - Study in Adult Ph-positive ALL Phase 2
Suspended NCT04554459 - Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL Phase 2
Recruiting NCT06025682 - Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO